Filtricine is a clinical stage biotechnology company targeting metabolic vulnerabilities in cancer and metabolic diseases. Our technology termed Targeted Nutrients Deprivation (TND) is a method to deplete from the bloodstream nutrients specifically required by cancer cells but not by normal cells. Our first product is a food product – a suite of complete replacement meals that lack several cancer-promoting nutrients. Filtricine initiated its first clinical trial at Stanford University Medical Center using our patented meal plan, Tality™ as the sole source of nutrition in prostate cancer patients. Patients are provided the meal plan for 28 days. The replacement meal plan was safe, and patients showed good compliance. Two metastatic patients in the initial cohort of ten showed a significant decline in PSA.
Privately Funded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):